On this page
Benign familial neonatal seizures (KCNQ2)
This condition causes seizures in infants, usually starting within the first few days of life, and is linked to changes in the KCNQ2 gene. The seizures often stop on their own, and most affected children develop typically without long-term neurological problems.
Available at Jeen Health
Clinical tests that include this
Overview
Benign familial neonatal seizures (BFNS) is a genetic disorder primarily affecting newborns, causing seizures that usually begin during the first week of life. Despite the distress these seizures can cause families, they are generally considered 'benign' because they often stop spontaneously within a few weeks or months, and most children go on to have typical development [PMID:31505527]. BFNS is considered rare, though its exact prevalence is not well established. This condition is one of the more common causes of neonatal-onset epilepsy with a generally favourable prognosis.
Symptoms & clinical features
The hallmark symptom of BFNS is the onset of recurrent seizures in otherwise healthy full-term infants. These seizures typically appear between the second and seventh day of life [PMID:24151040]. They can vary in presentation but commonly involve stiffening of the body (tonic posturing), rhythmic twitching, or staring spells and changes in breathing patterns. Sometimes, the seizures are brief and may only affect one side of the body or just a limb. The infant's neurological examination between seizure episodes is often normal, which helps distinguish BFNS from other more severe forms of neonatal epilepsy. There are usually no other significant health problems experienced by the infant in association with BFNS.
Video: Genetics 101
Affected organs
BFNS primarily affects the brain, specifically its electrical activity, leading to seizures. It does not typically cause structural changes in the brain or affect the function of other organ systems. The neurological development of the child is generally unaffected in the long term, once the seizure activity has resolved.
Risks & severity
The seizures in BFNS usually begin in the first week after birth and often spontaneously stop within six months of age, sometimes even sooner [PMID:24151040]. The long-term prognosis is generally excellent; most children achieve typical developmental milestones without any lasting neurological issues. However, a small proportion of individuals, estimated around 10-15%, may experience seizures later in life, often in adolescence or adulthood [PMID:31505527]. These later-onset seizures are typically well-controlled with standard anti-epileptic medications. In rare instances, more severe forms of developmental and epileptic encephalopathy have been linked to KCNQ2 changes, but this is less common for individuals with classic BFNS.
Genetic causes
Benign familial neonatal seizures (KCNQ2) is caused by pathogenic variants in the KCNQ2 gene. This gene provides instructions for making a protein that forms part of a potassium channel. These channels are crucial for controlling the electrical activity of nerve cells (neurons) in the brain. They help to stabilise the electrical charge across the neuron's membrane, which is vital for preventing uncontrolled firing of nerve impulses. When there is a pathogenic change in the KCNQ2 gene, the potassium channels may not function correctly, leading to an imbalance in electrical activity in the brain and thus causing seizures [PMID:24151040].
- KCNQ2 potassium voltage-gated channel subfamily Q member 2
Inheritance pattern
Benign familial neonatal seizures (KCNQ2) is inherited in an autosomal dominant pattern. This means that a person only needs one copy of the altered KCNQ2 gene in each cell to develop the condition. If a parent has a pathogenic variant in KCNQ2, there is a 50% chance with each pregnancy that their child will inherit the altered gene and subsequently develop the condition. This holds true regardless of the child's sex. Sometimes, the genetic change occurs spontaneously in the affected individual and is not inherited from either parent. This is known as a de novo variant.
Each child has a 50% chance of inheriting the pathogenic variant, regardless of sex.
Diagnosis & testing
Diagnosis of BFNS is typically suspected based on an infant's clinical presentation, characterised by seizures occurring within the first week of life in an otherwise healthy baby, often with a family history of similar episodes. An electroencephalogram (EEG) may show specific patterns during seizures which support the diagnosis. The definitive diagnosis is confirmed through genetic testing, which identifies a pathogenic variant in the KCNQ2 gene. In the UK, genetic testing for neonatal epilepsies, including KCNQ2-related conditions, may be arranged through the NHS Genomic Medicine Service (GMS) pathways, often following referral from a paediatric neurologist or a clinical genetics service. This testing aligns with relevant R-codes for epilepsies.
Management & lifestyle
The management of BFNS primarily focuses on controlling the seizures and providing supportive care. As seizures in BFNS often resolve spontaneously, medication may not always be necessary, or it may be prescribed for a short duration. If anti-seizure medication is used, it is typically chosen to be safe and effective for newborns. Regular follow-up with a paediatrician or paediatric neurologist is important to monitor seizure activity and overall development. Families often benefit from genetic counselling to understand the inheritance pattern and implications for future family planning. Because the condition typically has a favourable outcome, the focus is generally on reassurance and monitoring rather than aggressive long-term treatment.
UK care pathway
In the UK, individuals and families affected by genetic conditions like BFNS are supported through the NHS Genomic Medicine Service (GMS). If BFNS is suspected, a general practitioner or neonatologist can make a referral to a paediatric neurologist or a clinical genetics service. These specialists can arrange appropriate diagnostic tests, including genomic testing, which often falls under specific R-codes for neonatal onset epilepsies. Genetic counsellors are available to provide comprehensive information about the condition, its inheritance pattern, implications for other family members, and support options.
Frequently asked questions
Will my child definitely develop seizures if they have a change in the KCNQ2 gene?
If your child has a pathogenic variant in the KCNQ2 gene associated with BFNS, it is highly likely they will experience seizures in the neonatal period. However, the severity and duration of these seizures can vary among affected individuals.
Do KCNQ2 seizures cause long-term brain damage?
For most children with BFNS, the seizures are not associated with long-term brain damage, and developmental outcomes are typically good. The term 'benign' reflects this generally favourable prognosis.
How is BFNS treated in the UK?
In the UK, treatment for BFNS is managed by paediatric neurologists. They may prescribe anti-seizure medications if needed, but often the seizures spontaneously stop. Monitoring and support for the family are key components of care through the NHS.
What is the chance of future children inheriting BFNS?
If BFNS is inherited from a parent, there is a 50% chance with each pregnancy that a child will inherit the pathogenic 'KCNQ2' variant. If the genetic change arose spontaneously in your child (de novo), the chance for future children to be affected is generally low but can be discussed in detail with a genetic counsellor.
Can adults who had BFNS as babies experience seizures later in life?
While most individuals with BFNS have no further seizures after infancy, a small percentage may experience seizures later in childhood, adolescence, or adulthood. These later-onset seizures are typically manageable with medication.